Showing 1 - 20 of 459 results
ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.
ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.
ANSTO is Australia’s nuclear centre of excellence. It has a mandated role to advise the Australian Government on all nuclear and science technology matters.
To enable the production of nuclear medicine, ANSTO operates manufacturing, processing and distribution facilities in Sydney.
The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.
Supporting healthcare professionals in Australia with easy-to-access resources related to ANSTO’s Gentech® Generator.
With a well-established portfolio of nuclear research and the operation of Australia's only nuclear reactor OPAL, ANSTO scientists conduct both fundamental and applied research on fuel for current, advanced, and future nuclear technology systems.
Congress marks watershed moment for nuclear medicine and ANSTO
Combining scientific expertise with more than $1.3 billion in unique operational assets to provide optimal radioactive waste solutions.
Nuclear Reaction Analysis (NRA) detects charged particles and is used predominantly to determine concentrations and depth profiles of the lighter elements.
The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.
Seven of Australia’s top nuclear medicine professionals have been briefed on ANSTO’s plans to manage radioactive waste, as well as to support nuclear medicine innovation in Australia.